Dipyridamole and Olanzapine drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Dipyridamole (dipyridamole) and Olanzapine (olanzapine). Common drug interactions include calcium ionised increased among females and cardiac output decreased among males.

The phase IV clinical study analyzes what interactions people have when they take Dipyridamole and Olanzapine. It is created by eHealthMe based on reports of 23 people who take the same drugs from the FDA, and is updated regularly.

What is Dipyridamole?

Dipyridamole has active ingredients of dipyridamole. eHealthMe is studying from 5,998 Dipyridamole users. Check the latest studies of Dipyridamole.

What is Olanzapine?

Olanzapine has active ingredients of olanzapine. It is often used in bipolar disorder. eHealthMe is studying from 69,242 Olanzapine users. Check the latest studies of Olanzapine.



On Jul, 16, 2026

23 people who take Dipyridamole and Olanzapine together, and have interactions are studied.

Dipyridamole and Olanzapine drug interactions.

What are the common drug interactions of Dipyridamole and Olanzapine, by gender? *:

female:

  1. Calcium ionised increased
  2. Death
  3. Fall
  4. Limb injury
  5. Abnormal behaviour
  6. Dyspnoea (difficult or laboured respiration)
  7. Sleep apnoea syndrome (a sleep-related disorder in which the effort to breathe is diminished or absent)
  8. Alanine aminotransferase increased
  9. Blood alkaline phosphatase increased
  10. Blood glucose increased

male:

  1. Cardiac output decreased
  2. Cardiomegaly (increased size of heart than normal)
  3. Systolic dysfunction (impaired ventricular contraction)
  4. Abdominal pain upper
  5. Back pain
  6. Cardiovascular disorder (heart diseases)
  7. Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
  8. Constipation
  9. Corneal bleeding
  10. Dysarthria (speech disorder)

What are the common drug interactions of Dipyridamole and Olanzapine, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Cardiac output decreased
  2. Cardiomegaly (increased size of heart than normal)
  3. Chest discomfort
  4. Dyspnoea (difficult or laboured respiration)
  5. Hallucination, auditory (perceiving sounds without auditory stimulus)
  6. Heart rate increased
  7. Mental impairment (a condition affecting the body, perhaps through sight or hearing loss, a mobility difficulty or a health condition)
  8. Mitral valve incompetence (inefficient heart valve)
  9. Myocarditis (inflammation of heart muscle myocardium)
  10. Cardiomyopathy (weakening of the heart muscle)

40-49:

n/a

50-59:

  1. Calcium ionised increased
  2. Sleep apnoea syndrome (a sleep-related disorder in which the effort to breathe is diminished or absent)
  3. Blood glucose increased
  4. Cerebrovascular accident (sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture)
  5. Dysarthria (speech disorder)
  6. Dyspnoea (difficult or laboured respiration)
  7. Haematocrit increased
  8. Muscular weakness (muscle weakness)
  9. Overdose

60+:

  1. Fall
  2. Death
  3. Constipation
  4. Corneal bleeding
  5. Electrocardiogram qt prolonged
  6. Fluid retention (an abnormal accumulation of fluid in the blood)
  7. Gastric disorder (disease of stomach)
  8. Hepatitis (inflammation of the liver)
  9. Hospitalisation
  10. Hypertension (high blood pressure)

What are the existing conditions these people have? *

  1. High Blood Pressure: 5 people, 21.74%
  2. Dementia (madness): 5 people, 21.74%
  3. Osteoporosis (bones weak and more likely to break): 4 people, 17.39%
  4. Affective Disorder (mental disorder): 3 people, 13.04%
  5. Asthma: 3 people, 13.04%
  6. Depression: 3 people, 13.04%
  7. Urticaria (rash of round, red welts on the skin that itch intensely): 3 people, 13.04%
  8. Pain: 3 people, 13.04%
  9. Psychotic Disorder: 3 people, 13.04%
  10. Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 3 people, 13.04%

* Approximation only. Some reports may have incomplete information.

Do you take Dipyridamole and Olanzapine?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Dipyridamole and Olanzapine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Dipyridamole:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Olanzapine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Dipyridamole and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Olanzapine and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on dipyridamole and olanzapine (the active ingredients of Dipyridamole and Olanzapine, respectively), and Dipyridamole and Olanzapine (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: